Twist Bioscience (NASDAQ:TWST) Lifted to Hold at Zacks Investment Research

Twist Bioscience (NASDAQ:TWST) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California. “

Several other research firms have also recently weighed in on TWST. JPMorgan Chase & Co. cut Twist Bioscience from a “neutral” rating to an “underweight” rating and set a $100.00 price objective on the stock. in a research report on Friday, February 5th. Robert W. Baird increased their price objective on Twist Bioscience from $125.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, February 5th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $110.50.

TWST opened at $127.64 on Thursday. Twist Bioscience has a 1-year low of $25.72 and a 1-year high of $214.07. The stock’s fifty day simple moving average is $131.27 and its 200 day simple moving average is $127.75. The stock has a market cap of $6.21 billion, a PE ratio of -34.04 and a beta of 0.83.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Wednesday, February 3rd. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.02. Twist Bioscience had a negative return on equity of 44.62% and a negative net margin of 155.31%. The business had revenue of $28.16 million for the quarter, compared to analysts’ expectations of $25.26 million. Analysts predict that Twist Bioscience will post -3.03 earnings per share for the current year.

In other news, SVP Paula Green sold 246 shares of the business’s stock in a transaction that occurred on Monday, January 25th. The stock was sold at an average price of $193.00, for a total transaction of $47,478.00. Following the completion of the sale, the senior vice president now owns 22,496 shares in the company, valued at $4,341,728. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $166.88, for a total value of $333,760.00. Following the sale, the chief executive officer now owns 433,096 shares of the company’s stock, valued at approximately $72,275,060.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 157,027 shares of company stock valued at $26,389,861. 7.00% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Credit Suisse AG increased its holdings in shares of Twist Bioscience by 1,743.6% during the fourth quarter. Credit Suisse AG now owns 846,581 shares of the company’s stock valued at $119,613,000 after acquiring an additional 800,661 shares in the last quarter. William Blair Investment Management LLC increased its holdings in shares of Twist Bioscience by 153.1% during the fourth quarter. William Blair Investment Management LLC now owns 751,255 shares of the company’s stock valued at $106,145,000 after acquiring an additional 454,483 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Twist Bioscience by 11.8% during the fourth quarter. BlackRock Inc. now owns 3,499,004 shares of the company’s stock valued at $494,375,000 after acquiring an additional 370,176 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Twist Bioscience by 48.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 970,977 shares of the company’s stock valued at $137,189,000 after buying an additional 317,301 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Twist Bioscience by 14.5% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,850,717 shares of the company’s stock valued at $261,488,000 after buying an additional 234,339 shares during the last quarter. Hedge funds and other institutional investors own 87.90% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading: Market Perform

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.